Salute e Benessere

Sobi® and Enable Injections announce agreement to develop and distribute…

"We are dedicated to advancing innovative solutions for the treatment of rare diseases, and this agreement with Enable Injections marks an important step in fulfilling that commitment," said "We are dedicated to advancing innovative solutions for the treatment of rare diseases, and this agreement with Enable Injections marks an important step in fulfilling that commitment," said Lydia Abad-Franch, MD, Head of R&D, Medical Affairs, and Chief Medical Officer at Sobi…
PR Newswire
12/09/2024

Alchemab appoints Co-Founder Jane Osbourn as Chief Executive Officer

Jane, was awarded an Order of the British Empire (OBE) and Scrip's Lifetime Achievement Award in 2019 for services to drug discovery, development and biotechnology. She is a Venture Partner at SV Health Investors, has served as a Director of Babraham Bioscience Technologies, Cambridge Enterprise, the Crick Translational Advisory Group, and was Chair of the Board of Directors of the UK BioIndustry Association. Jane, was awarded an Order of the British Empire (OBE) and Scrip's Lifetime...
PR Newswire
12/09/2024

CIZZLE BIOTECHNOLOGY ANNOUNCES GROUNDBREAKING COLLABORATION WITH MOFFITT CANCER…

A Pioneering Study: A Pioneering Study: This collaboration is part of Moffitt's Phase 2 program, "Using Biomarkers for Diagnosis, Risk Stratification of Post-treatment Recurrence and Long-Term Survival of Lung Cancer." Led by Dr. Lary Robinson, Director of Moffitt's Lung Cancer Early Detection Center, the study will evaluate Cizzle's CIZ1B biomarker's ability to detect lung cancer early, aiming to reduce false positives and unnecessary interventions caused by CT scans. Strategic US...
PR Newswire
12/09/2024

Biogen Board Appoints Two New Independent Directors

Dr. Lloyd Minor and Prof Sir Menelas Pangalos bring significant scientific expertise and considerable experience in medicine research and development BiogenInc. (Nasdaq: BIIB) Board of Directors (the “Board”) today announced the appointments of two new independent directors, Lloyd B. Minor, M.D., effective October 1, 2024, and Sir Menelas (Mene) Pangalos, Ph.D., effective January 1, 2025. Dr. Minor is currently the Dean of the Stanford University School of Medicine and Vice President for...
Nasdaq GlobeNewswire
12/09/2024

Natural Dyes Market worth $6.4 billion by 2029 - Exclusive Report by…

Browse in-depth TOC on "Natural Dyes Market". Browse in-depth TOC on "Natural Dyes Market". 210 – Tables 89 – Figures 220 – Pages Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=78173284 "Plant Based Dyes is projected to be the fastest growing type of natural dyes, in terms of value, during the forecast period." Natural dyes which are derived from various parts of plants, including pods, bark, leaves, fruits and leaves are called...
PR Newswire
12/09/2024

Alex Therapeutics has signed an exclusive agreement with Navamedic for the…

Parkinson's disease is a neurodegenerative disorder associated with loss of motor skills and non-motor functions such as cognitive ability, which can make it difficult to manage treatments. Digital health tools provide an opportunity to support patients with functions such as reminders and treatment logs. Parkinson's disease is a neurodegenerative disorder associated with loss of motor skills and non-motor functions such as cognitive ability, which can make it difficult to manage treatments...
PR Newswire
12/09/2024

Trading by management and close relations of management

Please read the full announcement in PDF Attachment 2024_36_Trading_By_Management
Nasdaq GlobeNewswire
12/09/2024

QL Biopharm Presented Results from Phase 1c Clinical Study on its Novel…

The presentation titled 'ZT002, a novel ultra long-acting GLP-1 receptor agonist in adults with overweight or obesity: A randomized, placebo-controlled, multiple ascending dose phase 1c study' highlighted recent findings on QL Biopharm's lead drug candidate ZT002 - a novel ultra long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA) in development for obesity with monthly subcutaneous administration. The presentation titled'ZT002, a novel ultra long-acting GLP-1 receptor agonist in...
PR Newswire
12/09/2024

ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted…

ITM gains exclusive global development and commercialization rights to Debiopharm's first-in-class, peptide-based theranostic pair which combines therapeutic compound, Debio 0228 ([ 177 Lu]Lu-DPI-4452) and diagnostic imaging agent, Debio 0328 ([ 68 Ga]Ga-DPI-4452) to target Carbonic Anhydrase IX (CA IX) Debiopharm to receive upfront, development and regulatory milestone payments of approximately €300 million, as well as commercial milestones and low double-digit royalties...
Nasdaq GlobeNewswire
12/09/2024

Bavarian Nordic Provides Update on the Mpox Vaccine Supply Situation

COPENHAGEN, Denmark, September 12, 2024– Bavarian Nordic A/S (OMX: BAVA), the vaccine manufacturer of MVA-BN ®, the only approved non-replicating smallpox and mpox vaccine (marketed as JYNNEOS ®, IMVAMUNE ®and IMVANEX ® ) today provided an update of its supply and manufacturing activities in support of the ongoing mpox outbreak.Since the declaration of mpox as a Public Health Emergency of Continental Security (PHECS) by the Africa Centers for Disease Control (CDC) and the subsequent...
Nasdaq GlobeNewswire
12/09/2024

Rising Demand for Microelectronic Medical Implants Propels Market Growth at…

This report provides a comprehensive analysis of the global and regional markets for microelectronic medical implants, utilizing data from 2023, estimates for 2024, and projections for the period from 2024 to 2029. It examines key trends within the market, segmented by product types such as pacemakers, defibrillators, neurostimulators, hearing implants, ocular implants, and others, and applications including cardiology, neurology, audiology, and ophthalmology. The analysis covers regional…
PR Newswire
12/09/2024

SOPHiA GENETICS Announces Updates on SOPHiA UNITY at ESMO 2024

SOPHiA UNITY, the pioneering initiative by SOPHiA GENETICS, harnesses multimodal data and analytics to drive innovation from a global network. The bar for innovation in oncology is increasing as indications become more fragmented, more complex and requiring larger datasets. No single institution can address this challenge alone. SOPHiA GENETICS launched SOPHiA UNITY to meet this challenge, harmonizing high-quality, diverse, multimodal data at scale, leveraging the collective intelligence of…
PR Newswire
12/09/2024

Berlin Heals Strengthens Executive Leadership Team

"Brumfield is a talented medical device executive with a track record of bringing innovative technologies to market. With Berlin Heals' focus on a revolutionary treatment for heart failure, we are thrilled to have someone of Brumfield's cardiac rhythm and heart failure expertise leading the team at Berlin Heals," said Dr.Ulf Berg, Chairman of the Board. "Together with Brumfield's strategic and commercial expertise and Berlin Heals' outstanding team of innovators and…
PR Newswire
12/09/2024

Biocomposites to distribute its NanoBone® product range in the UK

NanoBone's patented technology consists of nanostructured hydroxyapatite embedded in a silica gel matrix, which is suspended in a hydrogel/polymer silica carrier. This formulation provides the fullest support for bone regeneration - providing comparable healing rate to autograft and osteoinductive properties, but without the costs and complications of harvesting. NanoBone is preloaded and ready-to-use in a wide variety of applications to maximise flexibility and efficiency during procedures. ...
PR Newswire
12/09/2024

POLYTECH Expands Portfolio with New Opticon® Plus Breast Implant

Meeting Market Needs with Collaborative Innovation The development of Opticon® Plus is the outcome of a collaborative effort, driven by feedback from leading global plastic surgeons. "Opticon® Plus was designed to offer a new anatomical option that complements our existing range, addressing specific needs that surgeons identified," stated Prof. Dr.Karsten Hemmrich, CEO of POLYTECH. "This implant is a result of direct input from the field, ensuring it meets the demands of both...
PR Newswire
12/09/2024

Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on…

Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancersParis, France, and Houston, Texas, September 12, 2024.As part of its effort to develop innovative treatments for people living with rare cancers, Sanofi has entered into an exclusive licensing agreement with RadioMedix, Inc., a US clinical-stage biotechnology company developing radiopharmaceuticals for PET imaging and targeted alpha therapy (TAT) against unmet...
Nasdaq GlobeNewswire
12/09/2024

Santhera Announces Half-Year 2024 Financial Results and Provides Corporate…

Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on September 12, 2024, at 14:30 CEST / 13:30 BST / 08:30 EDT. Details are at the end of this news release.Revenue from contracts with customers of CHF 14.1 million (H1-2023: CHF 3.9 million)Operating result of CHF -17.7 million (H1-2023: CHF -20.3 million) and net result ofCHF -15.3 million (H1-2023: CHF -23.3 million)AGAMREE® (vamorolone) launched in Germany and Austria as first European markets; North...
Nasdaq GlobeNewswire
12/09/2024

Vivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney…

Vivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney Function Data and Execution of Strategy to Advance Varoglutamstat in Kidney Disease Primary focus is developing varoglutamstat, a Phase 2 investigational medicine with potential to improve kidney function in patients with kidney diseaseStatistically significant benefit of varoglutamstat on prospectively defined key kidney function endpoint (eGFR 1 ) and significant reduction of pro-inflammatory...
Nasdaq GlobeNewswire
12/09/2024

Genespire appoints Karen Aiach-Pignet as Chief Executive Officer

PRESS RELEASE Genespire appoints Karen Aiach-Pignet as Chief Executive Officer Karen's appointment bolsters Genespire's position as a leader in in-vivo lentiviral gene therapy Milan, Italy, 12 September 2024– Genespire, a biotechnology company developing off-the-shelf gene therapies for pediatric patients affected by genetic diseases, today announces the appointment of Karen Aiach-Pignet as Chief Executive Officer following Dr. Julia Berretta, the former CEO, stepping down...
Nasdaq GlobeNewswire
12/09/2024

BIOVAXYS ANNOUNCES CLOSING OF THIRD TRANCHE OF PRIVATE PLACEMENT

Each Unit consists of one common share in the capital of the Company (each, a "Share") and one whole common share purchase warrant (each, a "Warrant"), whereby each Warrant is convertible into one additional Share at an exercise price of $0.15 until September 11, 2026, being the date that is 24 months from the date of issue. Each Unit consists of one common share in the capital of the Company (each, a " Share ") and one whole common share purchase warrant (each, a…
PR Newswire
12/09/2024

Nontuberculous Mycobacterial Infection Market to Exhibit Growth at a CAGR of…

Key Takeaways from the Nontuberculous Mycobacterial Infection Market Report Key Takeaways from the Nontuberculous Mycobacterial Infection Market Report Discover which therapies are expected to grab the major nontuberculous mycobacterial infection market share @Nontuberculous Mycobacterial Infection Market Report Nontuberculous Mycobacterial Infection Overview Nontuberculous mycobacteria (NTM) infections are diseases caused by bacteria from the Mycobacterium genus, excluding...
PR Newswire
11/09/2024

Teva to Present at the Bank of America 2024 Global Healthcare Conference

To access a live webcast of the presentation, visit Teva's Investor Relations website athttps://ir.tevapharm.com/Events-and-Presentations.An archived version of the webcast will be available within 24 hours after the end of the live discussion. About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global pharmaceutical leader with a category-defying portfolio, harnessing our generics expertise and stepping up innovation to continue the momentum behind the...
Nasdaq GlobeNewswire
11/09/2024

Annual Report 2023/24 - Strengthened commercial focus after challenging year

ANNOUNCEMENT NO. 273 11 September 2024Annual Report 2023/24 (1 July 2023 - 30 June 2024) Strengthened commercial focus after challenging year ChemoMetec's revenue fell by 8% in 2023/24 to DKK 407.4 million, and operating profit (EBITDA) was down by 26% to DKK 186.2 million. Revenue was adversely affected by a 35% decline in sales of instruments, while sales of consumables and services were up by 13% in total. During the year, ChemoMetec initiated a gradual launch of the XcytoMatic...
Nasdaq GlobeNewswire
11/09/2024

Guidance for the 2024/25 financial year

ANNOUNCEMENT NO. 272 11 September 2024 Guidance for the 2024/25 financial yearChemoMetec has today approved the annual report for 2023/24, including the guidance for 2024/25, which is considered inside information.For 2024/25, ChemoMetec expects revenue in the range of DKK 435-450 million (2023/24: DKK 407.4 million) and EBITDA in the range of DKK 216-223 (2023/24: DKK 186.2 million).The annual report for 2023/24, which is released along with this announcement, sets out the...
Nasdaq GlobeNewswire
11/09/2024
Altri  Comunicati